Search
SYNB1020
go.drugbank.com/drugs/DB17667InvestigationalIt was initially designed to convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016;[L45988] however, the manufacturer … discontinued further development of SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study.
Mestranol
go.drugbank.com/drugs/DB01357ApprovedWithdrawnThe 3-methyl ether of ethinyl estradiol. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL contraceptives.
Categories: Hormonal Contraceptives for Systemic UsePozanicline
go.drugbank.com/drugs/DB05458InvestigationalABT-089 is a neuronal nicotinic acetylcholine receptor agonist that may have therapeutic utility for the treatment of several neurological disorders including Alzheimer, Attention Deficit Hyperactivity
Acetergamine
go.drugbank.com/drugs/DB21015ExperimentalAcetergamine is a small molecule drug. Acetergamine has a monoisotopic molecular weight of 297.18 Da.
Categories: Heterocyclic Compounds with 4 or More RingsAVI-5126
go.drugbank.com/drugs/DB05726InvestigationalAVI-526 works by silencing a gene known as c-myc, a key regulatory gene involved in cardiovascular restenosis. … AVI-526 is an improved formulation of [AVI-4557], developed for use on Vein Grafts before use in Heart by-Pass Graft Surgery.
Myrcludex B
go.drugbank.com/drugs/DB14853InvestigationalMyrcludex B is under investigation in clinical trial NCT03546621 (A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination
AZD-5991
go.drugbank.com/drugs/DB14792InvestigationalAZD-5991 is under investigation in clinical trial NCT03218683 (Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies.).
Beta-(1,3)-D glucan
go.drugbank.com/drugs/DB16468InvestigationalCategories: Experimental Unapproved Treatments for COVID-19Valethamate
go.drugbank.com/drugs/DB13497InvestigationalCategories: Drugs for Functional Gastrointestinal DisordersMuraglitazar
go.drugbank.com/drugs/DB06510InvestigationalMuraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes. … In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment is associated with a substantial reduction in triglycerides (TGs), an increase in HDL-C, and a modest decrease